Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build
Moraiya Unit Reinspection Expected In June
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
